Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

In a report released yesterday, from CICC maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$133.71. In addition to CIC...

CICC Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)

RemeGen Co. Ltd. Class H ( ($HK:9995) ) just unveiled an update. RemeGen Co., Ltd. announced that China’s National Medical Products Administration ...

RemeGen Wins NMPA Nod to Start Clinical Trial of Bispecific ADC RC288

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Regeneron, with a price target of $825.00. Bansal covers the ...

Wells Fargo Sticks to Its Hold Rating for Regeneron (REGN)

The latest announcement is out from Regulus Resources ( ($TSE:REG) ). Regulus Resources has adopted a shareholder rights plan aimed at preventing c...

Regulus Resources Adopts Poison Pill as AntaKori Sulphide Project Advances

Creactives Group S.p.A. ( ($IT:CREG) ) has issued an update. Creactives Group S.p.A., a Verona-based AI specialist for supply chain solutions deliv...

Creactives Publishes Half-Year 2025 Consolidated Report for Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medios AG (MEDOF), Regeneron (REGN) and Siemens Heal...

Wall Street Analysts Are Bullish on Top Healthcare Picks

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has shared an update. RemeGen reported strong product sales revenue of about RMB2.31 billion for 2025, up 3...

RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access

An announcement from Creactives Group S.p.A. ( ($IT:CREG) ) is now available. Creactives Group reported a robust first half of fiscal 2025/26, with...

Creactives boosts recurring revenues and partner sales as balance sheet strengthens

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has provided an update. RemeGen has obtained approval from China’s National Medical Products Administration...

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

In a report released on March 20, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron, with a price target of $967.00. The comp...

Regeneron (REGN) Receives a Buy from Goldman Sachs

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Electrocore (ECOR) and Regeneron (REGN) with bullish...

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN)

Friday may be a volatile day for the S&P 500 (SPX) and the Nasdaq 100 (NDX), as $5.7 trillion worth of options tied to individual U.S. stocks, inde...

Get Ready for a $5.7 Trillion ‘Triple-Witching’ Event on Friday

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has issued an update. RemeGen Co., Ltd. has scheduled a board meeting for March 27, 2026, to review and app...

RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. The Impact of Dupilumab Treatment on Anxie...

Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron today and set a price target of $890.00. Tewari covers the Healthcare sector, f...

Jefferies Remains a Buy on Regeneron (REGN)

Regis Healthcare Ltd. ( ($AU:REG) ) has provided an update. Regis Healthcare Limited has notified the market that 125,816 performance rights, class...

Current Quarter	$1.21	Next Quarter	$1.19
Current Year	$4.84	Next Year	$5.07
QoQ Growth	-1.7%	YoY Growth	+4.8%
3Y EPS CAGR	+0.0%	Target Price	$81.53
Consensus	Buy	Upside	+4.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$78.35	0.00%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$78.35	0%	1.21M
3
4
5
6

REG

REG

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel